AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Wesco International Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

IGM Biosciences, Inc. (IGMS) � Form 4 filing dated 07/02/2025

Baker Bros. Advisors LP and affiliated investment funds (667, L.P. and Baker Brothers Life Sciences, L.P.) reported the receipt of 953 fully-vested restricted stock units (RSUs) on 06/30/2025. The RSUs were issued to Felix J. Baker in lieu of a $11,500 board retainer under the company’s Outside Director Compensation Policy. No cash was paid for the shares (price reported as $0).

Post-transaction indirect beneficial ownership stands at

  • 357,048 common shares held for the benefit of 667, L.P.
  • 3,763,362 common shares held for the benefit of Baker Brothers Life Sciences, L.P.
The Baker entities remain both �10% owners� and directors by deputization of IGMS.

The filing is administrative in nature—reflecting routine director compensation rather than open-market buying or selling—and does not alter the group’s sizable strategic stake in the company.

IGM Biosciences, Inc. (IGMS) � Comunicazione Form 4 datata 02/07/2025

Baker Bros. Advisors LP e i fondi di investimento affiliati (667, L.P. e Baker Brothers Life Sciences, L.P.) hanno riportato il ricevimento di 953 unità azionarie vincolate completamente maturate (RSU) il 30/06/2025. Le RSU sono state assegnate a Felix J. Baker in sostituzione di un compenso di 11.500 $ previsto per il consiglio di amministrazione secondo la politica di compenso per direttori esterni della società. Non è stato pagato alcun importo in contanti per queste azioni (prezzo riportato pari a 0 $).

La proprietà indiretta beneficiaria post-transazione ammonta a

  • 357.048 azioni ordinarie detenute per conto di 667, L.P.
  • 3.763.362 azioni ordinarie detenute per conto di Baker Brothers Life Sciences, L.P.
Le entità Baker rimangono sia “proprietari del 10%� sia direttori per delega di IGMS.

La comunicazione ha carattere amministrativo—riflettendo una normale compensazione per direttore piuttosto che operazioni di acquisto o vendita sul mercato aperto—e non modifica la consistente partecipazione strategica del gruppo nella società.

IGM Biosciences, Inc. (IGMS) � Presentación del Formulario 4 fechada el 02/07/2025

Baker Bros. Advisors LP y fondos de inversión afiliados (667, L.P. y Baker Brothers Life Sciences, L.P.) reportaron la recepción de 953 unidades de acciones restringidas totalmente adquiridas (RSU) el 30/06/2025. Las RSU fueron emitidas a Felix J. Baker en lugar de una retención de director de $11,500 bajo la Política de Compensación para Directores Externos de la empresa. No se pagó efectivo por las acciones (precio reportado como $0).

La propiedad indirecta beneficiaria tras la transacción es de

  • 357,048 acciones comunes en beneficio de 667, L.P.
  • 3,763,362 acciones comunes en beneficio de Baker Brothers Life Sciences, L.P.
Las entidades Baker continúan siendo tanto “propietarios del 10%� como directores por delegación de IGMS.

La presentación es de carácter administrativo—refleja la compensación rutinaria de directores en lugar de compras o ventas en el mercado abierto—y no altera la significativa participación estratégica del grupo en la empresa.

IGM ë°”ì´ì˜¤ì‚¬ì´ì–¸ìŠ�, Inc. (IGMS) â€� 2025ë…� 7ì›� 2ì¼ìž Form 4 제출

Baker Bros. Advisors LP ë°� ê´€ë � íˆ¬ìž íŽ€ë“�(667, L.P. ë°� Baker Brothers Life Sciences, L.P.)ê°€ 2025ë…� 6ì›� 30ì¼ì— 953ê°œì˜ ì™„ì „ ì·¨ë“ ì œí•œ ì£¼ì‹ ë‹¨ìœ„(RSU)ë¥� 수령했다ê³� 보고했습니다. ì� RSUëŠ� 회사ì� 외부 ì´ì‚¬ ë³´ìƒ ì •ì±…ì—� 따른 11,500달러 ì´ì‚¬íš� 보수 대ì‹� Felix J. Bakerì—게 발행ë˜ì—ˆìŠµë‹ˆë‹�. 주ì‹ì—� 대í•� 현금 ì§€ê¸‰ì€ ì—†ì—ˆìœ¼ë©°(ë³´ê³ ë� ê°€ê²©ì€ 0달러)입니ë‹�.

거래 í›� ê°„ì ‘ì � 실질 소유권ì€

  • 357,048 보통주가 667, L.P.ë¥� 위해 보유 중입니다.
  • 3,763,362 보통주가 Baker Brothers Life Sciences, L.P.ë¥� 위해 보유 중입니다.
Baker 계열사는 IGMSì� â€�10% 소유주â€�ì´ìž 대ë¦� ì´ì‚¬ ìžê²©ì� 유지하고 있습니다.

ì´ë²ˆ ì œì¶œì€ í–‰ì •ì ì¸ 성격으로—ì¼ìƒì ì� ì´ì‚¬ ë³´ìƒì� ë°˜ì˜í•� 것ì´ë©� 공개 시장ì—서ì� 매수ë‚� 매ë„와ëŠ� ë¬´ê´€í•˜ë©°â€”ê·¸ë£¹ì˜ íšŒì‚¬ ë‚� ìƒë‹¹í•� ì „ëžµì � 지분ì—ëŠ� ë³€í•¨ì´ ì—†ìŠµë‹ˆë‹¤.

IGM Biosciences, Inc. (IGMS) � Dépôt du formulaire 4 daté du 02/07/2025

Baker Bros. Advisors LP et les fonds d’investissement affiliés (667, L.P. et Baker Brothers Life Sciences, L.P.) ont déclaré avoir reçu 953 unités d’actions restreintes entièrement acquises (RSU) le 30/06/2025. Ces RSU ont été attribuées à Felix J. Baker en lieu et place d’une rémunération de 11 500 $ prévue pour le conseil d’administration selon la politique de rémunération des administrateurs externes de la société. Aucun paiement en espèces n’a été effectué pour ces actions (prix déclaré : 0 $).

La propriété bénéficiaire indirecte après la transaction s’élève à

  • 357 048 actions ordinaires détenues pour le compte de 667, L.P.
  • 3 763 362 actions ordinaires détenues pour le compte de Baker Brothers Life Sciences, L.P.
Les entités Baker restent à la fois « propriétaires de 10 % » et administrateurs par délégation »å’I³Ò²Ñ³§.

Le dépôt est de nature administrative � reflétant une rémunération habituelle des administrateurs plutôt qu’un achat ou une vente sur le marché ouvert � et ne modifie pas la participation stratégique importante du groupe dans la société.

IGM Biosciences, Inc. (IGMS) � Form 4 Einreichung vom 02.07.2025

Baker Bros. Advisors LP und angeschlossene Investmentfonds (667, L.P. und Baker Brothers Life Sciences, L.P.) meldeten den Erhalt von 953 vollständig unverfallbaren Restricted Stock Units (RSUs) am 30.06.2025. Die RSUs wurden Felix J. Baker als Ersatz für eine 11.500 $ Vorstandsvergütung gemäß der Outside Director Compensation Policy des Unternehmens zugeteilt. Für die Aktien wurde kein Bargeld gezahlt (gemeldeter Preis: 0 $).

Nach der Transaktion beträgt das indirekte wirtschaftliche Eigentum

  • 357.048 Stammaktien, gehalten zugunsten von 667, L.P.
  • 3.763.362 Stammaktien, gehalten zugunsten von Baker Brothers Life Sciences, L.P.
Die Baker-Einheiten bleiben sowohl â€�10%-·¡¾±²µ±ð²Ô³Ùü³¾±ð°ùâ€� als auch bevollmächtigte Direktoren von IGMS.

Die Einreichung ist administrativer Natur � sie spiegelt die routinemäßige Vergütung von Direktoren wider und keine Käufe oder Verkäufe am offenen Markt � und ändert nichts an dem erheblichen strategischen Anteil der Gruppe am Unternehmen.

Positive
  • Continued large insider ownership: Baker-controlled funds still hold over 4 million shares, maintaining strong alignment with public shareholders.
  • Transparency and timely Section 16 compliance reinforces good corporate governance practices.
Negative
  • None.

Insights

TL;DR: Routine RSU grant; total Baker Bros. stake unchanged—neutral for valuation.

This Form 4 records a small, non-cash grant of 953 RSUs to Felix Baker for board service, leaving the Baker complex with roughly 4.1 million IGMS shares across two funds. Because the shares were issued in lieu of director fees at no cost, there is no signal of incremental insider buying pressure or fundamental change in conviction. The group’s >10 % ownership and board influence remain intact, underscoring long-term alignment but providing no new catalyst.

TL;DR: Filing confirms compliance with Section 16; immaterial transaction.

The disclosure demonstrates proper reporting of director compensation under Section 16 rules. All parties explicitly disclaim beneficial ownership beyond their pecuniary interests, highlighting robust governance procedures. Material impact is negligible, yet continued transparency from a large shareholder is positive for investors� trust.

IGM Biosciences, Inc. (IGMS) � Comunicazione Form 4 datata 02/07/2025

Baker Bros. Advisors LP e i fondi di investimento affiliati (667, L.P. e Baker Brothers Life Sciences, L.P.) hanno riportato il ricevimento di 953 unità azionarie vincolate completamente maturate (RSU) il 30/06/2025. Le RSU sono state assegnate a Felix J. Baker in sostituzione di un compenso di 11.500 $ previsto per il consiglio di amministrazione secondo la politica di compenso per direttori esterni della società. Non è stato pagato alcun importo in contanti per queste azioni (prezzo riportato pari a 0 $).

La proprietà indiretta beneficiaria post-transazione ammonta a

  • 357.048 azioni ordinarie detenute per conto di 667, L.P.
  • 3.763.362 azioni ordinarie detenute per conto di Baker Brothers Life Sciences, L.P.
Le entità Baker rimangono sia “proprietari del 10%� sia direttori per delega di IGMS.

La comunicazione ha carattere amministrativo—riflettendo una normale compensazione per direttore piuttosto che operazioni di acquisto o vendita sul mercato aperto—e non modifica la consistente partecipazione strategica del gruppo nella società.

IGM Biosciences, Inc. (IGMS) � Presentación del Formulario 4 fechada el 02/07/2025

Baker Bros. Advisors LP y fondos de inversión afiliados (667, L.P. y Baker Brothers Life Sciences, L.P.) reportaron la recepción de 953 unidades de acciones restringidas totalmente adquiridas (RSU) el 30/06/2025. Las RSU fueron emitidas a Felix J. Baker en lugar de una retención de director de $11,500 bajo la Política de Compensación para Directores Externos de la empresa. No se pagó efectivo por las acciones (precio reportado como $0).

La propiedad indirecta beneficiaria tras la transacción es de

  • 357,048 acciones comunes en beneficio de 667, L.P.
  • 3,763,362 acciones comunes en beneficio de Baker Brothers Life Sciences, L.P.
Las entidades Baker continúan siendo tanto “propietarios del 10%� como directores por delegación de IGMS.

La presentación es de carácter administrativo—refleja la compensación rutinaria de directores en lugar de compras o ventas en el mercado abierto—y no altera la significativa participación estratégica del grupo en la empresa.

IGM ë°”ì´ì˜¤ì‚¬ì´ì–¸ìŠ�, Inc. (IGMS) â€� 2025ë…� 7ì›� 2ì¼ìž Form 4 제출

Baker Bros. Advisors LP ë°� ê´€ë � íˆ¬ìž íŽ€ë“�(667, L.P. ë°� Baker Brothers Life Sciences, L.P.)ê°€ 2025ë…� 6ì›� 30ì¼ì— 953ê°œì˜ ì™„ì „ ì·¨ë“ ì œí•œ ì£¼ì‹ ë‹¨ìœ„(RSU)ë¥� 수령했다ê³� 보고했습니다. ì� RSUëŠ� 회사ì� 외부 ì´ì‚¬ ë³´ìƒ ì •ì±…ì—� 따른 11,500달러 ì´ì‚¬íš� 보수 대ì‹� Felix J. Bakerì—게 발행ë˜ì—ˆìŠµë‹ˆë‹�. 주ì‹ì—� 대í•� 현금 ì§€ê¸‰ì€ ì—†ì—ˆìœ¼ë©°(ë³´ê³ ë� ê°€ê²©ì€ 0달러)입니ë‹�.

거래 í›� ê°„ì ‘ì � 실질 소유권ì€

  • 357,048 보통주가 667, L.P.ë¥� 위해 보유 중입니다.
  • 3,763,362 보통주가 Baker Brothers Life Sciences, L.P.ë¥� 위해 보유 중입니다.
Baker 계열사는 IGMSì� â€�10% 소유주â€�ì´ìž 대ë¦� ì´ì‚¬ ìžê²©ì� 유지하고 있습니다.

ì´ë²ˆ ì œì¶œì€ í–‰ì •ì ì¸ 성격으로—ì¼ìƒì ì� ì´ì‚¬ ë³´ìƒì� ë°˜ì˜í•� 것ì´ë©� 공개 시장ì—서ì� 매수ë‚� 매ë„와ëŠ� ë¬´ê´€í•˜ë©°â€”ê·¸ë£¹ì˜ íšŒì‚¬ ë‚� ìƒë‹¹í•� ì „ëžµì � 지분ì—ëŠ� ë³€í•¨ì´ ì—†ìŠµë‹ˆë‹¤.

IGM Biosciences, Inc. (IGMS) � Dépôt du formulaire 4 daté du 02/07/2025

Baker Bros. Advisors LP et les fonds d’investissement affiliés (667, L.P. et Baker Brothers Life Sciences, L.P.) ont déclaré avoir reçu 953 unités d’actions restreintes entièrement acquises (RSU) le 30/06/2025. Ces RSU ont été attribuées à Felix J. Baker en lieu et place d’une rémunération de 11 500 $ prévue pour le conseil d’administration selon la politique de rémunération des administrateurs externes de la société. Aucun paiement en espèces n’a été effectué pour ces actions (prix déclaré : 0 $).

La propriété bénéficiaire indirecte après la transaction s’élève à

  • 357 048 actions ordinaires détenues pour le compte de 667, L.P.
  • 3 763 362 actions ordinaires détenues pour le compte de Baker Brothers Life Sciences, L.P.
Les entités Baker restent à la fois « propriétaires de 10 % » et administrateurs par délégation »å’I³Ò²Ñ³§.

Le dépôt est de nature administrative � reflétant une rémunération habituelle des administrateurs plutôt qu’un achat ou une vente sur le marché ouvert � et ne modifie pas la participation stratégique importante du groupe dans la société.

IGM Biosciences, Inc. (IGMS) � Form 4 Einreichung vom 02.07.2025

Baker Bros. Advisors LP und angeschlossene Investmentfonds (667, L.P. und Baker Brothers Life Sciences, L.P.) meldeten den Erhalt von 953 vollständig unverfallbaren Restricted Stock Units (RSUs) am 30.06.2025. Die RSUs wurden Felix J. Baker als Ersatz für eine 11.500 $ Vorstandsvergütung gemäß der Outside Director Compensation Policy des Unternehmens zugeteilt. Für die Aktien wurde kein Bargeld gezahlt (gemeldeter Preis: 0 $).

Nach der Transaktion beträgt das indirekte wirtschaftliche Eigentum

  • 357.048 Stammaktien, gehalten zugunsten von 667, L.P.
  • 3.763.362 Stammaktien, gehalten zugunsten von Baker Brothers Life Sciences, L.P.
Die Baker-Einheiten bleiben sowohl â€�10%-·¡¾±²µ±ð²Ô³Ùü³¾±ð°ùâ€� als auch bevollmächtigte Direktoren von IGMS.

Die Einreichung ist administrativer Natur � sie spiegelt die routinemäßige Vergütung von Direktoren wider und keine Käufe oder Verkäufe am offenen Markt � und ändert nichts an dem erheblichen strategischen Anteil der Gruppe am Unternehmen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RAYMUND STEVEN A

(Last) (First) (Middle)
225 W. STATION SQUARE DRIVE
SUITE 700

(Street)
PITTSBURGH PA 15219

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
WESCO INTERNATIONAL INC [ WCC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2025 A 60.4747(1) A $0 28,269.7874 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents dividend equivalent rights ("DERs") in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on restricted stock units ("RSUs") held by the Reporting Person. Each DER is the economic equivalent of one share of Issuer's common stock and vests on the same schedule as the underlying award.
/s/ Michele Nelson, as Attorney-in-Fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many IGMS shares did Baker Bros. acquire in the latest Form 4?

953 fully-vested restricted stock units were granted on 06/30/2025.

What is Baker Bros.� total indirect ownership in IGMS after the transaction?

Approximately 357,048 shares via 667, L.P. and 3,763,362 shares via Baker Brothers Life Sciences, L.P.

Was any cash paid for the RSUs reported on this Form 4?

No. The RSUs were issued at $0 in lieu of a $11,500 director retainer fee.

Why are the reporting persons classified as 10% owners of IGMS?

Their aggregate holdings exceed 10 % of IGMS outstanding common stock, triggering Section 16 reporting.

Does the filing indicate insider sentiment toward IGMS stock?

The grant is routine compensation rather than a discretionary purchase, so it offers no strong sentiment signal.
Wesco Intl

NYSE:WCC

WCC Rankings

WCC Latest News

WCC Latest SEC Filings

WCC Stock Data

9.44B
47.80M
1.95%
97.21%
2.88%
Industrial Distribution
Wholesale-electrical Apparatus & Equipment, Wiring Supplies
United States
PITTSBURGH